Reported about 7 hours ago
Terns Pharmaceuticals and Rhythm Pharmaceuticals, two lesser-known biotechs, are developing innovative weight loss treatments. Terns is awaiting results from its oral GLP-1 therapy, TERN-601, while Rhythm is seeking label expansions for its existing drug, Imcivree. Both companies operate in a growing anti-obesity market and could see significant stock price increases depending on their clinical trial successes, although risks loom due to potential setbacks.
Source: YAHOO